Justice Department Moves to Reclassify Marijuana, Unlocking Major Tax Changes for $47 Billion Industry

WASHINGTON — The U.S. Department of Justice on April 23 announced it will move to reclassify marijuana as a less dangerous substance, a landmark shift in federal drug policy with profound implications for the nation's $47 billion cannabis industry. The proposed rule, initiated under a directive from President Donald Trump, would move state-regulated medical marijuana from its current Schedule I classification alongside heroin to the less restrictive Schedule III category, which includes substances like ketamine and testosterone. While the measure stops short of full federal legalization, it represents one of the most significant changes to U.S. drug policy in decades. The move aims to align federal regulations more closely with the reality in the vast majority of states, where cannabis is legal for either medical or recreational use. Acting Attorney General Todd Blanche stated the government would also fast-track a broader effort to reclassify all uses of the plant. For the thousands of small and mid-sized businesses in this sector, the immediate, tangible impact of this reclassification is overwhelmingly financial. In our experience, the single greatest operational burden for cannabis companies has been Section 280E of the Internal Revenue Code, a punitive provision that has prevented them from deducting ordinary business expenses like rent, payroll, and marketing simply because they dealt with a Schedule I substance. This forced them to pay taxes on gross profits, not net income, creating an enormous and often unsustainable cash flow drain. Rescheduling to Schedule III effectively nullifies Section 280E for these businesses, allowing them to operate under the same tax rules as any other legal enterprise. This is not just a minor adjustment; it is a fundamental change that will dramatically improve profitability and stability. Navigating this new landscape requires careful planning, and C&S Finance Group LLC offers expert tax preparation and compliance services to help businesses capitalize on these long-awaited changes. Contact us at csfinancegroup.com to ensure your financial strategy is aligned with the new regulations. The most significant consequence of the reclassification is the potential relief from the heavy tax burden imposed by Section 280E of the Internal Revenue Code. Enacted in the 1980s, the provision prohibits businesses involved in “trafficking” Schedule I or II substances from taking standard business deductions. According to industry experts, the removal of this restriction would be “life-changing” for many state-legal cannabis businesses, potentially unlocking billions of dollars in economic activity and creating tens of thousands of jobs. Market researcher BDSA projects the legal U.S. cannabis market will reach $47 billion in sales by 2026. With the ability to deduct expenses, companies are expected to see a significant boost in profitability, which could in turn attract more mainstream investment and facilitate access to traditional financial services, which have largely been unavailable due to federal prohibition. Beyond the financial benefits, the policy shift is expected to significantly lower barriers to scientific and medical research. Scientists have long argued that the Schedule I classification, which designates a drug as having no accepted medical use and a high potential for abuse, has severely hampered clinical studies into cannabis's therapeutic potential. In a statement, Acting Attorney General Blanche said the new classification will allow for more robust research on the substance's safety and efficacy, ultimately providing patients with better care and doctors with more reliable information. Companies like Tilray Brands and Canopy Growth, which are already researching pharmaceutical uses for cannabis in pain management and anxiety, are poised to benefit. This federal action comes as public opinion and state laws have moved decisively in favor of legalization. According to the National Conference of State Legislatures, 40 states now permit medical use of cannabis, while 24 states and the District of Columbia have legalized it for recreational adult use. A 2024 Pew Research Center survey found that nearly six in ten Americans support legalizing recreational marijuana. Irwin Simon, CEO of Tilray Brands, called the announcement a “pivotal moment” where federal policy is “finally aligning with science, medicine, and most importantly, patient needs.” However, the move is not without its critics. Opponents argue that loosening federal rules primarily serves the interests of an “addiction-for-profit industry” and disregards potential public health risks. The reclassification also leaves some questions unanswered, particularly how it will affect state-licensed businesses that operate in both the medical and recreational markets. The change does not legalize marijuana outright at the federal level, meaning possession and distribution outside of state-regulated systems remain illegal. The Justice Department's proposal will now undergo a formal rulemaking process, which includes a public comment period before a final rule is issued. Industry stakeholders, investors, and state regulators will be closely watching the implementation details from federal agencies, including the IRS and the Food and Drug Administration, to understand the full scope of this historic policy shift.